Crystalline 19-N-C3,3-disubstituted C21-N-pyrazolyl steroid

JP2026090610APending Publication Date: 2026-06-02SAGE THERAPEUTICS LLC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
SAGE THERAPEUTICS LLC
Filing Date
2026-03-05
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

There is a need for novel crystalline forms of steroids that can modulate brain excitability and serve as agents for the prevention and treatment of CNS-related disorders, as existing neurostimulant compounds may not effectively address these conditions.

Method used

Development of 19-nor compounds in specific crystalline forms, characterized by XRPD patterns, DSC, TGA, NMR, and DVS, which are converted through methods like static evaporation and slurry conversion, and administered to treat CNS-related disorders.

Benefits of technology

The crystalline forms of 19-nor steroids provide effective modulation of brain excitability and treatment of CNS disorders, including sleep disorders, mood disorders, and neurological conditions, with administration routes such as oral, parenteral, and transdermal.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026090610000018
    Figure 2026090610000018
  • Figure 2026090610000019
    Figure 2026090610000019
  • Figure 2026090610000020
    Figure 2026090610000020
Patent Text Reader

Abstract

To provide a crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid. [Solution] The present invention relates to formula (I) This invention relates to 19-nor-C3,3-disubstituted C21-pyrazolylsteroids, their crystalline solid form, and compositions, as disclosed in TIFF2026090610000017.tif3037. Methods for preparing the crystalline solid form of the 19-nor-C3,3-disubstituted C21-pyrazolylsteroid of formula (I), as well as methods for using the 19-nor-C3,3-disubstituted C21-pyrazolylsteroid of formula (I) or its crystalline solid form, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions are also disclosed herein.
Need to check novelty before this filing date? Find Prior Art